Several other research analysts also recently commented on WBA. Zacks Investment Research downgraded Walgreens Boots Alliance from a buy rating to a hold rating in a research note on Tuesday, March 6th. Barclays initiated coverage on Walgreens Boots Alliance in a research note on Thursday, March 8th. They issued an equal weight rating and a $76.00 target price for the company. BidaskClub downgraded Walgreens Boots Alliance from a sell rating to a strong sell rating in a research report on Thursday, March 22nd. TheStreet downgraded Walgreens Boots Alliance from a b- rating to a c+ rating in a research report on Tuesday, March 20th. Finally, Pivotal Research dropped their price target on Walgreens Boots Alliance from $73.00 to $69.00 and set a hold rating for the company in a research report on Friday, March 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $79.68.
NASDAQ WBA traded up $0.31 during trading hours on Friday, hitting $60.02. The company had a trading volume of 15,724,972 shares, compared to its average volume of 8,739,294. Walgreens Boots Alliance has a 52 week low of $59.07 and a 52 week high of $83.89. The company has a quick ratio of 0.45, a current ratio of 0.93 and a debt-to-equity ratio of 0.44. The company has a market cap of $59.20 billion, a P/E ratio of 11.77, a P/E/G ratio of 0.96 and a beta of 1.14.
Walgreens Boots Alliance (NASDAQ:WBA) last issued its earnings results on Thursday, June 28th. The pharmacy operator reported $1.53 EPS for the quarter, topping the consensus estimate of $1.47 by $0.06. Walgreens Boots Alliance had a return on equity of 21.22% and a net margin of 3.36%. The business had revenue of $34.33 billion during the quarter, compared to the consensus estimate of $34.15 billion. During the same quarter last year, the company earned $1.33 EPS. The firm’s revenue was up 14.0% compared to the same quarter last year. equities research analysts anticipate that Walgreens Boots Alliance will post 5.96 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 12th. Investors of record on Monday, August 20th will be issued a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a dividend yield of 2.93%. This is a boost from Walgreens Boots Alliance’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Friday, August 17th. Walgreens Boots Alliance’s dividend payout ratio (DPR) is currently 31.37%.
In related news, Director William C. Foote sold 2,736 shares of the firm’s stock in a transaction dated Wednesday, May 2nd. The stock was sold at an average price of $65.56, for a total transaction of $179,372.16. Following the transaction, the director now directly owns 13,679 shares of the company’s stock, valued at approximately $896,795.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 14.80% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Roof Eidam & Maycock ADV purchased a new position in Walgreens Boots Alliance in the 1st quarter worth approximately $1,877,000. Endurant Capital Management LP increased its stake in Walgreens Boots Alliance by 422.9% in the 4th quarter. Endurant Capital Management LP now owns 180,223 shares of the pharmacy operator’s stock worth $13,088,000 after purchasing an additional 145,759 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in Walgreens Boots Alliance by 17.2% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 116,893 shares of the pharmacy operator’s stock worth $8,489,000 after purchasing an additional 17,145 shares during the period. Mariner LLC increased its stake in Walgreens Boots Alliance by 92.0% in the 1st quarter. Mariner LLC now owns 120,317 shares of the pharmacy operator’s stock worth $7,877,000 after purchasing an additional 57,645 shares during the period. Finally, Altman Advisors Inc. purchased a new position in Walgreens Boots Alliance in the 4th quarter worth approximately $1,570,000. 60.27% of the stock is currently owned by institutional investors.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.